Inventiva Stock Soars 98% in a Year, Approaching a Key Resistance
Inventiva's stock is up 3.2% at midday this Tuesday, trading at 5.48 euros in a positively oriented Parisian market. The French biotech has shown a remarkable trajectory in recent months, with a performance of nearly 51% over three months and 98% over a year. This session is part of a generalized rebound of European indices, with the CAC 40 up 2.16% during the session.
Continued Growth and Upcoming Financial Milestones
Inventiva continues its ascent begun in recent quarters. The current price of 5.48 euros is significantly above its 200-day moving average, established at 3.92 euros, and also exceeds the 50-day moving average, at 5.08 euros. This positioning reflects a favorable underlying trend in the medium and long term. The company's financial calendar could be a short-term catalyst: the publication of the annual results for 2025 is scheduled for March 30. The market will then have concrete elements to assess the progress of clinical programs and the cash situation of the biotech, which is developing treatments for non-alcoholic steatohepatitis (NASH). The revenue for the first quarter of 2026 is expected on May 25.
Recent Progress and Technical Indicators
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
While today's progress reinforces the recent trend, several technical indicators call for caution. The RSI, which measures the relative strength of the movement, is at 52, a neutral zone that signals neither overbuying nor overselling. This level suggests that the stock still has potential room for growth before reaching overheated zones. However, the price is moving within a tight technical corridor. The nearest resistance is at 5.83 euros, while the support is at 5.00 euros. At 5.48 euros, the stock is approaching the upper limit of the Bollinger bands, set at 5.78 euros, which could hinder progress in the very short term. The monthly volatility, measured at 11.75, shows still significant fluctuations for this stock with a negative beta of -0.56, which historically tends to move in a decoupled manner from the market as a whole.
Position de trésorerie au 30/09/2025 de 97,6 millions d’euros (plus 24,7 millions d’euros en dépôts à court terme) ; revenus de 4,5 millions d'euros sur les neuf premiers mois de 2025 principalement liés à CTTQ ; flux opérationnels consommés de - 76,3 millions d’euros et flux d'investissement de - 25 millions d’euros ; flux de financement positifs de 103,4 millions d’euros incluant le produit net de la deuxième tranche du financement structuré. Offre publique en novembre 2025 d’ADS apportant un produit net d’environ 139,3 millions d’euros et estimation d’un horizon de trésorerie jusqu’à fin T1 2027 (pouvant aller jusqu’à mi-T3 2027 si exercice intégral de la Tranche 3 pouvant apporter 116,0 millions d'euros).
Risks mentioned
Besoin de capitaux supplémentaires pour financer les opérations
Risque que la Société utilise ses ressources plus rapidement que prévu
Incertitudes et risques liés aux essais cliniques et aux autorisations réglementaires
Dépendance au succès du lanifibranor et des résultats de l'essai NATiV3
Opportunities identified
Produit net de l’offre publique en novembre 2025 d’environ 139,3 millions d’euros renforçant la trésorerie
Exercice potentiel de la Tranche 3 pouvant apporter jusqu’à 116,0 millions d'euros supplémentaires
Paiement d'étape et avoirs liés à l’accord avec CTTQ (10 M$ et 5 M$)
Résultats principaux de l’essai NATiV3 attendus au second semestre 2026
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
